Reconsidering the Diagnosis and Management of Obinutuzumab-induced Acute Thrombocytopenia Authors: Shinya Fujita Published: 2025 To the Editor We read with great interest a recent case report describing obinutuzumab-induced acute thrombocytopenia mimicking immune thrombocytopenia (ITP) (1). This report highlights an uncommon but clinically significant adverse reaction to obinutuzumab therapy. However, we would like to raise several concerns regarding the diagnostic interpretation and therapeutic choices described in this article. First, the authors suggested an ITP-like mechanism based on elevated platelet-associated IgG, thrombopoietin levels, and immature platelet fraction. However, no bone marrow (BM) examination was performed to confirm preserved megakaryopoiesis at the time of platelet decline. This assessment is essential for distinguishing ITP from thrombocytopenia owing to a decreased production. According to the 2019 American Society of Hematology guidelines, BM evaluation should be considered in patients aged >60 years or with atypical presentations and these criteria were clearly met in this case (2). Second, the authors classified drug-induced thrombocytopenia as either non-immune, caused by direct cytotoxicity, or immune-mediated, involving antibody- or complement-dependent destruction. They argued that the rapid onset within 24 h of obinutuzumab infusion indicates an immune process distinct from typical drug-induced immune thrombocytopenia. However, the reported clinical courses of obinutuzumab-induced acute thrombocytopenia (OIAT) are highly variable; some patients recover within a few days (3), whereas others require several weeks of treatment (4). This variability suggests that OIAT is not a single immune-mediated entity, but a spectrum of various mechanisms, including immune destruction, a transient impairment of megakaryopoiesis, or both. Therefore, a BM examination at the nadir is crucial to confirm megakaryopoiesis and to guide mechanism-oriented management in individual cases. Third, the therapeutic rationale is inconsistent. Although the condition was described as ITP-like, the authors bypassed first-line treatments, such as corticosteroids or intravenous immunoglobulin, and instead initiated eltrombopag, a thrombopoietin receptor agonist generally reserved for chronic refractory ITP. Furthermore, they stated that no established treatment exists for OIAT yet proceeded with a specific agent, introducing an internal inconsistency. In conclusion, while the present case is clinically intriguing, the report would have benefited from a more rigorous diagnostic workup and a clearer therapeutic rationale. Given the heterogeneous nature of OIAT, early BM evaluation should not only refine the diagnosis but also inform individualized, mechanism-based treatment, such as immunosuppression (steroids/intravenous immunoglobulin) for peripheral destruction versus TPO-receptor agonists and temporary withholding of myelosuppressive agents when impaired megakaryopoiesis is evident. Future studies should include comprehensive immune and complement studies alongside the BM findings to better differentiate destruction from a decreased production and to standardize the management strategies for this poorly characterized entity. The author states that he has no Conflict of Interest (COI).